CN Patent

CN110511266B — 一种小分子多肽及其用途

Assigned to Nanfang Hospital of Southern Medical University · Expires 2022-08-30 · 4y expired

What this patent protects

本发明中公开一种小分子多肽及其用途。该小分子多肽KP‑6T具有显著抑制及逆转肾脏组织纤维化和CKD进展的作用，且无明显毒副作用，因此可用于制备有效抑制CKD进展的药物。与现有技术中公开的小分子多肽KP‑6相比，KP‑6T与KP‑6均可延缓晚期UUO小鼠的肾脏纤维化进展，但是KP‑6T中仅含有11个氨基酸，肽链更短，合成更容易、造价更低、并且更容易在体内吸收分布。

USPTO Abstract

本发明中公开一种小分子多肽及其用途。该小分子多肽KP‑6T具有显著抑制及逆转肾脏组织纤维化和CKD进展的作用，且无明显毒副作用，因此可用于制备有效抑制CKD进展的药物。与现有技术中公开的小分子多肽KP‑6相比，KP‑6T与KP‑6均可延缓晚期UUO小鼠的肾脏纤维化进展，但是KP‑6T中仅含有11个氨基酸，肽链更短，合成更容易、造价更低、并且更容易在体内吸收分布。

Drugs covered by this patent

Patent Metadata

Patent number
CN110511266B
Jurisdiction
CN
Classification
—
Expires
2022-08-30
Drug substance claim
No
Drug product claim
No
Assignee
Nanfang Hospital of Southern Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.